Leap Therapeutics,Inc. (NYSE:XON) Files An 8-K Other EventsItem 8.01 Other Events.
On April16, 2018, Leap Therapeutics,Inc. (the “Company”) issued a press release announcing new clinical and nonclinical data presented at the AACR Annual Meeting relating to the Company’s anti-DKK1 monoclonal antibody, DKN-01. Nonclincal experiments demonstrated the activity of DKK1 inhibition in enhancing innate immunity and the potential for combination with immune checkpoint inhibitors. The presentation also highlighted the preliminary results from the Company’s dose escalation phase of the clinical study evaluating DKN-01 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA®(pembrolizumab). The full text of the press release is filed as Exhibit99.1 to this Current Report on Form8-K and incorporated herein by reference.
Item 9.01.Financial Statements and Exhibits.
LEAP THERAPEUTICS, INC. ExhibitEX-99.1 2 a18-10115_1ex99d1.htm EX-99.1 Exhibit 99.1 Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting Cambridge,…To view the full exhibit click here About Leap Therapeutics,Inc. (NYSE:XON) Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform. Leap Therapeutics,Inc. (NYSE:XON) Recent Trading Information Leap Therapeutics,Inc. (NYSE:XON) closed its last trading session down -0.76 at 18.86 with shares trading hands.